Biotech startup Voronoi scraps IPO plan Startup has failed to draw enough bids for planned listing
Translated by Kim So-in 공개 2022-03-17 08:12:05
이 기사는 2022년 03월 17일 07:57 thebell 에 표출된 기사입니다.
South Korea’s biotech startup Voronoi has scrapped its plan to go public after getting lukewarm response from institutional investors in its two-day bookbuilding process.Voronoi has cancelled its initial public offering (IPO) plan as it only drew bids from some 20 institutions in its bookbuilding, according to industry sources on Tuesday. Most of the institutions decided not to make bids at the last minute.
“The company’s growth potential was high, but many of the institutions decided not to participate in the bookbuilding amid unfavorable market conditions,” an official at one asset management firm in Seoul said. “All of the asset managers I know made their final decisions to withdraw this time.”
Voronoi had to attract bids worth 100 billion won ($80 million) based on the bottom end of its price range, but the bids drawn were worth much less than that.
Voronoi was valued at 1.2 trillion won in its 100 billion won pre-IPO funding round in 2019, but had to lower its valuation following two failures in technology evaluations.
The biotech startup could have been the first unicorn going public in the country to benefit from a special exemption for listing. This allows companies to apply for preliminary review for listing on the Kosdaq if their market capitalization exceeds 500 billion won and pass technology evaluation from one independent evaluating agency instead of two. Voronoi received an A rating from Korea Technology Finance Corporation and valued itself at as high as 860 billion won in its registration statement.
Voronoi CEO Kim Dae-kwon himself conducted IR session for the firm’s successful market debut, but failed to attract positive response amid frozen investor sentiment toward biotech firms. (Reporting by Chan-mi Oh)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재 및 재배포 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- KT&G, 찻잔속 태풍 '행동주의 공세' 성장 플랜 속도낸다
- 백복인 KT&G 사장 "매출 증대 '경영 효율성' 제고 최우선"
- 이엔플러스, '2차전지 주역' 강태경 각자 대표 선임
- [코스닥 주총 돋보기]티에스아이 사외이사, 이사회 1회 출석당 400만원 '꿀보직'
- 한국알콜 행동주의 통했다…트러스톤 이사회 입성 성공
- 새 최대주주 맞은 '아우딘퓨쳐스', 화장품+신사업 밸류업 시동
- [증권사 IB, 유상증자 비즈니스 전략]KB증권, 코스닥 기업 집중 전략...SME본부까지 신설
- [증권사 PF-ABCP 긴급점검]한국증권, 신용보강 확 줄였지만 '브릿지론' 부담가중
- 대규모 차입부담 두산테스나, 믿을맨은 중장기 성장성
- [넘버원 K-가전 기술]위닉스, 50년 탑티어 '열교환기'의 힘